Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:38:53 2024-12-05 am EST			5-day change	1st Jan Change
1.832 ^EUR	-5.18%		-0.76%	-61.19%

Dec. 04	Valneva: the impact of chikungunya heavier than estimated (BMJ)	CF
Dec. 04	Valneva: Polar Capital drops below 5% stake	CF

Valneva: presentations planned at conferences

November 12, 2024 at 07:20 am EST

Valneva announces that members of its management team will make presentations and participate in meetings with institutional investors at upcoming conferences, in Boston on November 12, and London on November 19.

At these presentations, CEO Thomas Lingelbach and CFO Peter Bühler will review the company's key value drivers and expected catalysts, which include various clinical results in 2025.

Among the most notable results will be the key Phase 3 results for its Lyme disease vaccine candidate, for which Pfizer plans to submit regulatory submissions in Europe and the USA in 2026.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	PFIZER, INC.	25.70USD	+1.86%	-0.50%	143B
	VALNEVA	1.832EUR	-5.18%	-0.76%	330M

Latest news about Valneva

Valneva: the impact of chikungunya heavier than estimated (BMJ)	Dec. 04	CF
Valneva: Polar Capital drops below 5% stake	Dec. 04	CF
Valneva: positive three-year data for Ixchiq	Dec. 03	CF
Valneva's Chikungunya Vaccine Shows Positive Three-year Antibody Persistence	Dec. 03	MT
Valneva SE Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®	Dec. 03	CI
Valneva Seeks US FDA Nod for Label Extension of Chikungunya Vaccine	Nov. 26	MT
Valneva Submits Label Extension Application for Its Chikungunya Vaccine, IXCHIQ, to the U.S. FDA	Nov. 26	CI
Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ	Nov. 26	MT
Valneva: submitted a vaccine application to the FDA	Nov. 26	CF
Health Care Down as RFK Fears Mount -- Health Care Roundup	Nov. 15	DJ
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department	Nov. 15	DJ
Valneva: first vaccination in a trial with S4V	Nov. 14	CF
Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2	Nov. 13	CI
Valneva: presentations planned at conferences	Nov. 12	CF
Valneva SE Reports Earnings Results for the Nine Months Ended September 30, 2024	Nov. 07	CI
Valneva SE, Nine Months 2024 Earnings Call, Nov 07, 2024	Nov. 07
Valneva: return to operating profit for nine months	Nov. 07	CF
Valneva: 9-month sales up with ixiaro/jespect, outlook revised	Nov. 07	RE
Valneva: FDA Fast Track status for Shigella4V	Oct. 17	CF
Valneva Partnership Get Fast Track Designation for Tetravalent Shigella Vaccine Candidate	Oct. 17	MT
Valneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate	Oct. 16	MT
Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V	Oct. 16	CI
Valneva SE - Analyst/Investor Day	Oct. 10
Valneva: investor day in New York	Oct. 10	CF
Valneva: Bpifrance Participations below 10% of voting rights	Sep. 20	CF

Chart Valneva

Duration

Period

VLA: Dynamic Chart

Company Profile

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Employees

676

Sector

Biotechnology & Medical Research

Calendar

2025-02-18 - Q4 2024 Sales and Revenue Release

More about the company